A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma

British Journal of Haematology

Volumn 132, Issue 5, 2006, Pages 584-593

  Glasmacher, Axel ^a   Hahn, Corinna ^a   Hoffmann, Florian ^a   Naumann, Ralph ^b   Goldschmidt, Hartmut ^c   Von Lilienfeld Toal, Marie ^a   Orlopp, Katjana ^a   Schmidt Wolf, Ingo ^a   Gorschlüter, Marcus ^a  

^a UNIVERSITY OF BONN   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Multiple myeloma; Systematic review; Thalidomide

Indexed keywords

PROTEIN; THALIDOMIDE;

ADULT; CANCER RELAPSE; CANCER SURVIVAL; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; FEMALE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE MYELOMA; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; SURVIVAL TIME; THROMBOEMBOLISM;

CLINICAL TRIALS, PHASE II; DATA COLLECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; PERIPHERAL NERVOUS SYSTEM DISEASES; SURVIVAL RATE; THALIDOMIDE; TREATMENT OUTCOME;

EID: 33644898842     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05914.x     Document Type: Review

References (75)

1. Alexanian R. 1972 Combination chemotherapy for multiple myeloma Cancer 30 382 389
2. Alexanian R. Weber D. 2000 Thalidomide for resistant and relapsing myeloma Seminars in Hematology 37 Suppl 3 22 25
3. Alexanian R. Weber D. Anagnostopoulos A. Delasalle K. Wang M. Rankin K. 2003 Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma Seminars in Hematology 40 3 7
4. Anagnostopoulos A. Weber D. Rankin K. Delasalle K. Alexanian R. 2003 Thalidomide and dexamethasone for resistant multiple myeloma British Journal of Haematology 121 768 771
5. Barlogie B. Smith L. 1984 Effective treatment of advanced multiple myeloma refractory to alkylating agents New England Journal of Medicine 310 1353 1356
6. Barlogie B. Desikan R. Eddlemon P. Spencer T. Zeldis J. Munshi N. Badros A. Zangari M. Anaissie E. Epstein J. Shaughnessy J. Ayers D. Spoon D. Tricot G. 2001a Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients Blood 98 492 494
7. Barlogie B. Zangari M. Spencer T. Fassas A. Anaissie E. Badros A. Cromer J. Tricot G. 2001b Thalidomide in the management of multiple myeloma Seminars in Hematology 38 250 259
8. Barlogie B. Shaughnessy J. Tricot G. Jacobson J. Zangari M. Anaissie E. Walker R. Crowley J. 2004 Treatment of multiple myeloma Blood 103 20 32
9. Bertolini F. Mingrone W. Alietti A. Ferrucci P.F. Cocorocchio E. Peccatori F. Cinieri S. Mancuso P. Corsini C. Burlini A. Zucca E. Martinelli G. Cineri S. 2001 Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers Annals of Oncology 12 987 990
10. Bila J. Elezovic I. Tomin D. Gotic M. Mihaljevic B. Suvajdzic N. M. Cemerikic Sretenovic, V Boskovic D. 2003 Thalidomide treatment of patients with advanced multiple myeloma Abstract Hematology Journal 4 Suppl. 1 S233
11. Blade J. Samson D. Reece D. Apperley J. Björkstrand B. Gahrton G. Gertz M. Giralt S. Jagannath S. Vesole D. 1998 Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation British Journal of Haematology 102 1115 1123
12. Boulin M. Blanchet F. Isambert N. Solary E. Solier S. Collin B. Pernot C. Durnet-Archeray M.J. 2002 Thalidomide with or without dexamethasone for refractory multiple myeloma Therapie 57 524 529
13. Cavenagh J.D. Oakervee H. 2003 Thalidomide in multiple myeloma: current status and future prospects British Journal of Haematology 120 18 26
14. Cavo M. Zamagni E. Cellini C. Tosi P. Cangini D. Cini M. Valdre L. Palareti G. Masini L. Tura S. Baccarani M. 2002 Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy Blood 100 2272 2273
15. Chen C.I. Adesanya A. Sutton D.M. Brandwein J. Stewart A.K. 1999 Low-dose thalidomide in patients with advanced, refractory multiple myeloma Abstract Blood 94 Suppl. 1 308b
16. Del Vecchio M. Pitini V. Arrigo C. Aloi G. Procopio G. Alu M. La Torre I. Kalbakis K. Bajetta E. 2002 Thalidomide in relapsed multiple myeloma patients and changes in circulating TNF-alpha, IL-6, bFGF and VEGF Abstract Proceedings of the American Society of Clinical Oncology 21 278a
17. Dimopoulos M.A. Zervas K. Kouvatseas G. Galani E. Grigoraki V. Kiamouris C. Vervessou E. Samantas E. Papadimitriou C. Economou O. Gika D. Panayiotidis P. Christakis I. Anagnostopoulos N. 2001 Thalidomide and dexamethasone combination for refractory multiple myeloma Annals of Oncology 12 991 995
18. Dimopoulos M.A. Anagnostopoulos A. Weber D. 2003 Treatment of plasma cell dyscrasias with thalidomide and its derivatives Journal of Clinical Oncology 21 4444 4454
19. Dimopoulos M.A. Hamilos G. Zomas A. Gika D. Efstathiou E. Grigoraki V. Poziopoulos C. Xilouri I. Zorzou M.P. Anagnostopoulos N. Anagnostopoulos A. 2004 Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma Hematology Journal 5 112 117
20. Durie B.G.M. Stepan D.E. 2000 Efficacy of low dose thalidomide in multiple myeloma Electronic Journal of Oncology 1 1 8
21. Glasmacher A. von Lilienfeld-Toal M. 2005 The current status of thalidomide in the management of multiple myeloma Acta Haematologica 114 Suppl. 1 3 7
22. Glasmacher A. Naumann R. 2005 Empfehlungen zur Anwendung von Thalidomid bei Patienten mit einem multiplen Myelom Available at: v432005_07_19 DGHO.pdf; Last accessed: 19.07.2005
23. Gonzalez-Porras J.R. Garcia-Sanz R. Polo-Zarzuela M. Sureda A. Barrenetxea M. Alegre-Amor A. Grande-Garcia C. Perez R. Gutierrez-Perez O. Vargas-Pabon M. Del Campo M. Hernandez J. San Miguel J.F. 2003 ThaCyDex in relapsed/refractory multiple myeloma Abstract Hematology Journal 4 S234
24. Grosbois B. Bellissant E. Moreau P. Attal M. Zerbib R. 2001 Thalidomide (Thal) in the treatment of advanced multiple myeloma (MM). A prospective study of 120 patients Abstract Blood 98 163a
25. Guglielmelli T. Capella S. Mattioli G. Guerrasio A. Saglio G. 2003 Thalidomide at very low dosage may represent an effective therapy in relapsed and refractory multiple myeloma Abstract Blood 102 383b
26. Habeck M. 2003 Australia approves thalidomide Lancet Oncol. 4 713
27. Helgason H.H. Smit W.M. de Groot M.R. El Schenkeveld C. Neef C. Schaafsma M.R. 2002 Long term survival and complete remission of chemotherapy refractory multiple myeloma with thalidomide Abstract Blood 100 378b
28. Huang S.Y. Tang J.L. Yao M. Ko B.S. Hong R.L. Tsai W. Wang C.H. Tien H.F. Shen M.C. Chen Y.C. 2003 Reduction of leukocyte count is associated with thalidomide response in treatment of multiple myeloma Annals of Hematology 82 558 564
29. Hus M. Dmoszynska A. Soroka-Wojtaszko M. Jawniak D. Legiec W. Ciepnuch H. Hellmann A. Wolska-Smolen T. Skotnicki A. Manko J. 2001 Thalidomide treatment of resistant or relapsed multiple myeloma patients Haematologica 86 404 408
30. Hussein M.A. Elson P. Tso E.A. Karam M. Srkalovic G. 2003 Doxil, Vincristine, Decadron and Thalidomide (DVd-T) for relapsed/refractory multiple myeloma (RMM) Abstract Hematology Journal 4 S235 S236
31. Johnston R.E. Abdalla S.H. 2002 Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia Leukemia and Lymphoma 43 351 354
32. Juliusson G. Celsing F. Turesson I. Lenhoff S. Adriansson M. Malm C. 2000 Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma British Journal of Haematology 109 89 96
33. Kakimoto T. Hattori Y. Okamoto S. Sato N. Kamata T. Yamaguchi M. Morita K. Yamada T. Takayama N. Uchida H. Shimada N. Tanigawara Y. Ikeda Y. 2002 Thalidomide for the treatment of refractory multiple myeloma: association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome Japanese Journal of Cancer Research 93 1029 1036
34. Kees M. Dimou G. Sillaber C. Drach J. Ackermann J. Lechner K. Gisslinger H. 2003 Low dose thalidomide in patients with relapsed or refractory multiple myeloma Leukemia and Lymphoma 44 1943 1946
35. Kneller A. Raanani P. Hardan I. Avigdor A. Levi I. Berkowicz M. Ben Bassat I. 2000 Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug British Journal of Haematology 108 391 393
36. Kropff M.H. Lang N. Bisping G. Domine N. Innig G. Hentrich M. Mitterer M. Sudhoff T. Fenk R. Straka C. Heinecke A. Koch O.M. Ostermann H. Berdel W.E. Kienast J. 2003 Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma British Journal of Haematology 122 607 616
37. Kumar S. Gertz M.A. Dispenzieri A. Lacy M.Q. Geyer S.M. Iturria N.L. Fonseca R. Hayman S.R. Lust J.A. Kyle R.A. Greipp P.R. Witzig T.E. Rajkumar S.V. 2003 Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma Mayo Clinic Proceedings 78 34 39
38. Kyrcz-Krzemien S. Helbig G. Stella-Holowiecka B. Holowiecki J. 2003 [Preliminary results of monotherapy with thalidomide in recurrent and treatment resistant cases of multiple myeloma] Wiadomosci Lekarskie 56 227 232
39. Leleu X. Magro L. Fawaz A. Bauters F. Facon T. Yakoub-Agha I. 2002 Efficacy of a low dose of thalidomide in advanced multiple myeloma Blood 100 1519 1520
40. Mileshkin L. Biagi J.J. Mitchell P. Underhill C. Grigg A. Bell R. McKendrick J. Briggs P. Seymour J.F. Lillie K. Smith J.G. Zeldis J.B. Prince H.M. 2003 Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age Blood 102 69 77
41. Moehler T.M. Neben K. Benner A. Egerer G. Krasniqi F. Ho A.D. Goldschmidt H. 2001 Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy Blood 98 3846 3848
42. Myers B. Dolan G. 2002 Analysis of durability of response to thalidomide treatment for relapsed myeloma patients British Journal of Haematology 118 347
43. Neben K. Moehler T. Benner A. Kraemer A. Egerer G. Ho A.D. Goldschmidt H. 2002 Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma Clinical Cancer Research 8 3377 3382
44. Oakervee H.E. Gupta V. Smith M.L. Taussig D.C. Syndercombe-Court Y.D. Rohatiner A.Z. Lister T.A. Cavenagh J.D. 2001 Response to thalidomide can be predicted by paraprotein quantitation 14 days after initiating therapy Abstract British Journal of Haematology 113 Suppl. 1 40
45. Offidani M. Marconi M. Corvatta L. Olivieri A. Catarini M. Mele A. Brunori M. Candela M. Malerba L. Capelli D. Montanari M. Rupoli S. Leoni P. 2003 Combination therapy with thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma Abstract Hematology Journal 4 Suppl. 1 S230
46. Okikawa Y. Takimoto Y. Noda M. Imagawa J. Katayama Y. Sakai A. Okita H. Fujimura K. Kimura A. 2003 Single-agent thalidomide for advanced and refractory multiple myeloma Rinsho Ketsueki. Japanese Journal of Clinical Hematology 44 368 374
47. Osman K. Comenzo R. Rajkumar S.V. 2001 Deep venous thrombosis and thalidomide therapy for multiple myeloma New England Journal of Medicine 344 1951 1952
48. Palumbo A. Giaccone L. Bertola A. Pregno P. Bringhen S. Rus C. Triolo S. Gallo E. Pileri A. Boccadoro M. 2001 Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma Haematologica 86 399 403
49. Palumbo A. Bertola A. Falco P. Rosato R. Cavallo F. Bringhen S. Giaccone G. Musto P. Pregno P. Ciccone G. Boccadoro M. 2003 Low-dose thalidomide and dexamethasone improves survival in multiple myeloma patients. (Abstract) Hematology Journal 4 S233
50. Patriarca F. Sperotto A. Prosdocimo S. Geromin A. Zaja F. Fanin R. 2003 Thalidomide before autologous stem cell transplantation in VAD-refractory multiple myeloma patients Haematologica 88 597 599
51. Petrucci M.T. Palumbo G. Martini V. Levi A. Del Bianco P. Mandelli F. 2003 Thalidomide (Thal) an active agent for multiple myeloma (MM) does not chenge the prognosis of plasma cell leukemia (PCL) patients. Experience of a single center Abstract Hematology Journal 4 Suppl. 1 227
52. Pini M. Baraldi A. Pietrasanta D. Allione B. Depaoli L. Salvi F. Levis A. 2000 Low-dose of thalidomide in the treatment of refractory myeloma Haematologica 85 1111 1112
53. Rajkumar S.V. Fonseca R. Dispenzieri A. Lacy M.Q. Lust J.A. Witzig T.E. Kyle R.A. Gertz M.A. Greipp P.R. 2000 Thalidomide in the treatment of relapsed multiple myeloma Mayo Clinic Proceedings 75 897 901
54. Rajkumar S.V. Hayman S. Gertz M.A. Dispenzieri A. Lacy M.Q. Greipp P.R. Geyer S. Iturria N. Fonseca R. Lust J.A. Kyle R.A. Witzig T.E. 2002 Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma Journal of Clinical Oncology 20 4319 4323
55. Raza S.N. Veksler Y. Sabir T. Li Z. Anderson L. Jagannath S. 2000 Durable response to thalidomide in relapsed/refractory multiple myeloma (MM) Abstract Blood 96 Pt 1 168a 169a
56. Richardson P. Schlossman R. Jagannath S. Alsina M. Desikan R. Blood E. Weller E. Mitsiades C. Hideshima T. Davies F. Doss D. Freeman A. Bosch J. Patin J. Knight R. Zeldis J. Dalton W. Anderson K. 2004 Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity Mayo Clinic Proceedings 79 875 882
57. Rosinol L. Cibeira M.T. Blade J. Esteve J. Aymerich M. Rozman M. Segarra M. Cid M.C. Filella X. Montserrat E. 2004 Extramedullary multiple myeloma escapes the effect of thalidomide Haematologica 89 832 836
58. Schauvliege L. Janssens A. Vantilgorgh A. Offner F. Noens L. 2003 Thalidomide in relapsed and refractory multiple myeloma: a retrospective analysis of efficacy and toxicity Abstract Hematology Journal 4 Suppl. 1 228 229
59. Schey S.A. Cavenagh J. Johnson R. Child J.A. Oakervee H. Jones R.W. 2003 An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment Leukemia Research 27 909 914
60. Singhal S. Mehta J. Desikan R. Ayers D. Roberson P. Eddlemon P. Munshi N. Anaissie E. Wilson C. Dhodapkar M. Zeddis J. Barlogie B. 1999 Antitumor activity of thalidomide in refractory multiple myeloma New England Journal of Medicine 341 1565 1571
61. Tosi P. Zamagni E. Cellini C. Ronconi S. Patriarca F. Ballerini F. Musto P. Di Raimondo F. Ledda A. Lauria F. Masini L. Gobbi M. Vacca A. Ria R. Cangini D. Tura S. Baccarani M. Cavo M. 2002 Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma Haematologica 87 408 414
62. UK Myeloma Forum & The Nordic Myeloma Study Group 2005 Guidelines on the Diagnosis and Management of Multiple Myeloma 2005 Available at: Last accessed: 05.11.2005
63. Waage A. Gimsing P. Juliusson G. Turesson I. Gulbrandsen N. Eriksson T. Hjorth M. Nielsen J.L. Lenhoff S. Westin J. Wisloff F. 2004 Early response predicts thalidomide efficiency in patients with advanced multiple myeloma British Journal of Haematology 125 149 155
64. Weber D. 2003 Thalidomide and its derivatives: new promise for multiple myeloma Cancer Control 10 375 383
65. Weber D.M. Gavino M. Delasalle K. Rankin K. Giralt S. Alexanian R. 1999 Thalidomide alone or with dexamethasone for multiple myeloma Abstract Blood 94 Suppl. 1 604a
66. Weber D. Rankin K. Gavino M. Delasalle K. Alexanian R. 2003 Thalidomide alone or with dexamethasone for previously untreated multiple myeloma Journal of Clinical Oncology 21 16 19
67. Wechalekar A.D. Chen C.I. Sutton D. Reece D. Voralia M. Stewart A.K. 2003 Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma Leukemia and Lymphoma 44 1147 1149
68. Wu K.L. Schaafsma M.R. Lokhorst H.M. Wijermans P.W. van der Holt H.B. Sonneveld P. 2002 Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45% Nederlands Tijdschrift voor Geneeskunde 146 1445 1448
69. Yakoub-Agha I. Attal M. Dumontet C. Delannoy V. Moreau P. Berthou C. Lamy T. Grosbois B. Dauriac C. Dorvaux V. Bay J.O. Monconduit M. Harousseau J.L. Duguet C. Duhamel A. Facon T. 2002 Thalidomide in patients with advanced multiple myeloma: a study of 83 patients - report of the Intergroupe Francophone du Myelome (IFM) Hematology Journal 3 185 192
70. Yakoub-Agha I. Mohty M. Attal M. Marit G. Bulabois C.-E. Sotto J.J. Gratecos N. Rio B. Vernant J.P. Dib M. Garban F. Cahn J.Y. Jouet J.P. Facon T. 2003 Thalidomide (Thal) as salvage therapy for relapsed multiple myeloma (MM) after allogeneic stem cell transplantation (SCT) Abstract Blood 102 Pt 2 456b
71. Zangari M. Anaissie E. Barlogie B. Badros A. Desikan R. Gopal A.V. Morris C. Toor A. Siegel E. Fink L. Tricot G. 2001 Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy Blood 98 1614 1615
72. Zangari M. Siegel E. Barlogie B. Anaissie E. Saghafifar F. Fassas A. Morris C. Fink L. Tricot G. 2002 Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy Blood 100 1168 1171
73. Zangari M. Saghafifar F. Mehta P. Barlogie B. Fink L. Tricot G. 2003 The blood coagulation mechanism in multiple myeloma Seminars in Thrombosis and Hemostasis 29 275 282
74. Zangari M. Barlogie B. Anaissie E. Saghafifar F. Eddlemon P. Jacobson J. Lee C.K. Thertulien R. Talamo G. Thomas T. van Rhee F. Fassas A. Fink L. Tricot G. 2004 Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation British Journal of Haematology 126 715 721
75. Zervas K. Dimopoulos M.A. Hatzicharissi E. Anagnostopoulos A. Papaioannou M. Mitsouli C. Panagiotidis P. Korantzis J. Tzilianos M. Maniatis A. 2004 Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study Annals of Oncology 15 134 138